Rep. Bruce Westerman Sells Boston Scientific Co. (NYSE:BSX) Stock

Representative Bruce Westerman (R-Arkansas) recently sold shares of Boston Scientific Co. NYSE: BSX. In a filing disclosed on May 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on April 21st. The trade occurred in the Representative's "FISHER IRA" account.

Representative Bruce Westerman also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of UniCredit OTCMKTS: UNCRY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of CSX NASDAQ: CSX on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Siemens Aktiengesellschaft OTCMKTS: SIEGY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of GSK NYSE: GSK on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 4/21/2025.
• Sold $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 4/21/2025.
• Sold $15,001 - $50,000 in shares of NVIDIA NASDAQ: NVDA on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Chevron NYSE: CVX on 4/21/2025.

Boston Scientific Stock Up 1.1%

Boston Scientific stock traded up $1.14 during midday trading on Friday, hitting $106.00. 7,288,742 shares of the company's stock were exchanged, compared to its average volume of 6,365,351. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The company has a market cap of $156.83 billion, a PE ratio of 84.80, a P/E/G ratio of 2.79 and a beta of 0.68. The firm has a 50-day moving average of $98.98 and a two-hundred day moving average of $96.42. Boston Scientific Co. has a 12 month low of $71.88 and a 12 month high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The company's quarterly revenue was up 20.9% on a year-over-year basis. During the same period last year, the firm earned $0.56 earnings per share. As a group, analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP John Bradley Sorenson sold 2,657 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $104.41, for a total value of $277,417.37. Following the transaction, the executive vice president now owns 24,294 shares in the company, valued at approximately $2,536,536.54. This represents a 9.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the completion of the transaction, the chief executive officer now owns 1,535,706 shares in the company, valued at approximately $157,379,150.88. This trade represents a 9.67% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 265,820 shares of company stock worth $27,406,958. 0.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

Several hedge funds have recently modified their holdings of BSX. Norges Bank acquired a new position in shares of Boston Scientific during the fourth quarter valued at about $1,762,522,000. Capital World Investors increased its holdings in Boston Scientific by 28.7% in the 4th quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider's stock worth $2,492,041,000 after buying an additional 6,216,199 shares during the period. Wellington Management Group LLP increased its holdings in Boston Scientific by 10.2% in the 4th quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock worth $3,230,293,000 after buying an additional 3,344,571 shares during the period. GAMMA Investing LLC increased its holdings in Boston Scientific by 11,720.3% in the 1st quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after buying an additional 2,556,078 shares during the period. Finally, Axiom Investors LLC DE increased its holdings in Boston Scientific by 208.2% in the 4th quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider's stock worth $335,167,000 after buying an additional 2,535,007 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Robert W. Baird lifted their price target on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Erste Group Bank upgraded Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. StockNews.com raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. BTIG Research reissued a "buy" rating and set a $124.00 price target on shares of Boston Scientific in a research report on Wednesday, April 23rd. Finally, Barclays increased their price target on shares of Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Twenty-three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $114.74.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election. Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.